Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — Q2 2024 Earnings Presentation
30 slides from Sophia Genetics Sa's earnings presentation, Aug 6, 2024
Slide 1: Investor Presentation
Investor Presentation August 6, 2024
Slide 2: Cautionary notices
Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, pro
Slide 3: Contents
Contents § SOPHiA GENETICS’ mission to democratize data-driven medicine § SOPHiA DDMTM: The Platform at the heart of our mission § Q2 2024 Performance update 3 © SOPHiA GENETICS 2024
Slide 4: SOPHiA GENETICS at-a-glance
SOPHiA GENETICS at-a-glance 2024 70+ 780+ 1.8 Million+ 697 scientific 707 publications (as of Aug 2024) 4 © SOPHiA GENETICS 2024 (1) Data as of June 30, 2024.
Slide 5: © SOPHiA GENETICS 2023 | CONFIDENTIAL – For Internal Use Only
© SOPHiA GENETICS 2023 | CONFIDENTIAL – For Internal Use Only
Slide 6: For decades, health data has been produced in silos
For decades, health data has been produced in silos 6 © SOPHiA GENETICS 2024
Slide 7: SOPHiA GENETICS was founded to break data silos
SOPHiA GENETICS was founded to break data silos and expand access to … 7 © SOPHiA GENETICS 2024
Slide 8: Using AI to deliver world-class care across the globe
…by using AI to deliver world-class care to across the globe.
Slide 9: SOPHiA DDM is a decentralized analytics platform
SOPHiA DDMTM is a decentralized analytics platform which computes complex data and provides insights to Clinical and BioPharma customers 9 © SOPHiA GENETICS 2024
Slide 10: We are targeting a sizeable addressable market
We are targeting a sizeable addressable market Clinical market BioPharma market Generating insights from multimodal data Generating insights from multimodal data to help Clinicians with screening, early detection, to help BioPharma companies with drug diagnosis, therapy selection, and monitoring dis
Slide 11: The SOPHiA DDM Platform uniquely serves this market
The SOPHIA DDMTM Platform uniquely serves this market 11 © SOPHiA GENETICS 2024 (1) NPS Score reflects survey results users of SOPHiA DDMTM ’s core genomic module (i.e., SOPHiA DDM for Genomics) only and excludes survey results from users of add-on modules such as Alamut.
Slide 12: Global network of healthcare institutions share insights
Our vast, global network of healthcare institutions share insights and contribute to a collective intelligence 1 780+ 70+ 12 © SOPHiA GENETICS 2024 (1) Data as of June 30, 2024. (2) Includes core genomic customers and customers using add-on modules such as Alamut.
Slide 13: Contents
Contents § SOPHiA GENETICS’ mission to democratize data-driven medicine § SOPHiA DDMTM: The Platform at the heart of our mission § Q2 2024 Performance update 13 © SOPHiA GENETICS 2024
Slide 14: Industry-leading multimodal capabilities driven by AI
Industry-leading multimodal capabilities driven by AI makes SOPHiA DDMTM the platform of choice for actionable patient insights 14 © SOPHiA GENETICS 2024
Slide 15: SOPHiA DDM enables Clinical customers to become beacons of precision medicine
SOPHiA DDMTM enables Clinical customers to become beacons of precision medicine ILLUSTRATIVE GENOMIC OFFERING Consumption-based business model charges customers per analysis run on SOPHiA DDMTM 15 © SOPHiA GENETICS 2024
Slide 16: Customers choose SOPHiA DDM for accuracy, speed, decentralization, cost savings
Customers choose SOPHiA DDMTM for its accuracy, expedited turnaround time, decentralized approach, and cost savings 16 © SOPHiA GENETICS 2024
Slide 17: Comprehensive portfolio of SOPHiA DDM applications
Comprehensive portfolio of SOPHiA DDMTM applications serves customers across their precision medicine needs 17 © SOPHiA GENETICS 2024
Slide 18: Analysis volume on SOPHiA DDM is growing rapidly
Analysis volume on SOPHiA DDMTM is growing rapidly across all applications 362% 32% 26% 25% 19% 18 © SOPHiA GENETICS 2024 (1) Year-over-year analysis volume as of December 31, 2023. Analysis volume growth is presented excluding COVID-related volumes.
Slide 19: Data processed on SOPHiA DDM has exploded over the years
Data processed on SOPHiA DDMTM has exploded over the years 19 © SOPHiA GENETICS 2024 (1) Figures represent an estimate of total data processed on SOPHiA DDMTM as of December 31, 2023.
Slide 20: AI insights for BioPharma partners across the drug continuum
SOPHiA DDMTM leverages the advanced AI powering the platform as well as the real-time, real-world data computed daily to deliver valuable insights to our BioPharma partners across the drug continuum 20 © SOPHiA GENETICS 2024
Slide 21: Contents
Contents § SOPHiA GENETICS’ mission to democratize data-driven medicine § SOPHiA DDMTM: The Platform at the heart of our mission § Q2 2024 Performance update 21 © SOPHiA GENETICS 2024
Slide 22: Q2 2024 Highlights
Q2 2024 Highlights Strong Cost Management Buffers Loss; Robust New Business Momentum Expanding usage of SOPHiA DDM™ worldwide • Q2 analysis volume was ~87,000, representing 12% year-over-year growth Revenue $15.8 million • 457 core genomics customers as of Q2 2024, up from 434 in Q2 2023 vs. $15.1M
Slide 23: Growth drivers for 2024
Growth drivers for 2024 Potential catalysts for growth in 2024 Liquid Biopsy: Deploy new Liquid Biopsy offering worldwide with the help of BioPharma partners Solid tumors: Capitalize on the demand of increasingly complex signatures, including HRD U.S. market: Build off strong momentum and marquee na
Slide 24: 2024 annual guidance
2024 annual guidance FY 2023 FY 2024 YoY Category Key drivers results Guide improvement • Focus on accelerating new customers into routine usage faster • Capitalize on growing demand for Liquid Biopsy application, MSK- $65M - $67M 4% – 7% ACCESS® powered with SOPHiA DDMTM Revenue $62.4M (Updated) gr
Slide 25: Path to profitability in the next 2 years
Path to profitability in the next 2 years Near term path to profitability(1) Q2 2024 represents another quarter of 2026 strong cost management 2021 2022 2023 2024 2025 73.2% Adj. gross margin vs. 70.0% in Q2 2023 (2) 32% Adj. operating margin Improved adjusted operating improvement (3) loss by 32% t
Slide 26: Investment highlights
Investment highlights Sizable addressable ~$40B market market opportunity(1) Market-leading $400M+ 697 technology invested since scientific inception publications FY 2023 highlights Customers love Figures as of Dec 31, 2023 75 ~4% +87 NPS score among annualized new customers SOPHiA DDMTM SOPHiA DDMT
Slide 27: Democratizing Data-Driven Medicine, Together
+ oo ' *. SOPHIA * ee GENETICS” Democratizing Data-Driven Medicine, Together
Slide 28: Financial overview
Financial overview ($ in millions, except for margin data) Q2 2024 P&L Q2 2024 Q2 2023 Change Y/Y Total revenues $15.8 $15.1 5% Adjusted gross margin % 73.2% 70.0% +316bps Adjusted operating loss ($9.9) ($14.6) 32% Cash burn ($13.3)1 (13.3) 0%2 Balance sheet June 30, 2024 June 30, 2023 Change Y/Y Ca
Slide 29: Reconciliation of IFRS Financials to Adjusted Financials
Reconciliation of IFRS Financials to Adjusted Financials 2023 2024 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $13,966 $15,054 $16,303 $17,048 $62,371 $15,779 $15,808 Gross Profit $9,694 $10,047 $11,273 11,898 $42,913 $10,405 $10,776 Gross Margin 69% 67% 69% 70% 69% 66% 68%
Slide 30: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
Reconciliation of IFRS Revenue Growth to Constant Current Revenue Growth Excluding COVID-19-Related Revenue (Amounts in USD Thousands) Q2 2023 FY 2023 Q2 2024 Y-o-Y Growth IFRS Revenue $15,054 $62,371 $15,808 5% Current Period Constant Currency Impact (1) — — 179 Constant Currency Revenue $15,054 $6